171 related articles for article (PubMed ID: 29866747)
21. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
22. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
[TBL] [Abstract][Full Text] [Related]
23. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
25. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor.
Sun Y; Chen Z; Liu G; Chen X; Shi Z; Feng H; Yu L; Li G; Ding K; Huang H; Zhang Z; Xu S
Bioorg Chem; 2024 Feb; 143():107053. PubMed ID: 38159497
[TBL] [Abstract][Full Text] [Related]
27. TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer.
Hu X; Li G; Li S; Wang Q; Wang Y; Zhang P; Yang T; Yang B; Yu L; Liu Z
Biochem Biophys Res Commun; 2024 Jan; 694():149388. PubMed ID: 38150917
[TBL] [Abstract][Full Text] [Related]
28. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
29. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
30. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
[TBL] [Abstract][Full Text] [Related]
31. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
32. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of
Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
[TBL] [Abstract][Full Text] [Related]
35. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
[TBL] [Abstract][Full Text] [Related]
36. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Morrison CD; Chang JC; Keri RA; Schiemann WP
Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
[TBL] [Abstract][Full Text] [Related]
37. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
[TBL] [Abstract][Full Text] [Related]
38. Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S; Pansa MF; Paviolo NS; Castellaro AM; Andino DL; Nigra AD; García IA; Racca AC; Rodriguez-Berdini L; Angiolini V; Guantay L; Villafañez F; Federico MB; Rodríguez-Baili MC; Caputto BL; Drewes G; Madauss KP; Gloger I; Fernandez E; Gil GA; Bocco JL; Gottifredi V; Soria G
Clin Cancer Res; 2019 Jul; 25(13):4049-4062. PubMed ID: 30890549
[TBL] [Abstract][Full Text] [Related]
39. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.
Miao R; Wu Y; Zhang H; Zhou H; Sun X; Csizmadia E; He L; Zhao Y; Jiang C; Miksad RA; Ghaziani T; Robson SC; Zhao H
Sci Rep; 2016 Sep; 6():33121. PubMed ID: 27618777
[TBL] [Abstract][Full Text] [Related]
40. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
